The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
The new human papillomavirus (HPV) vaccine is a research breakthrough for pediatric/adolescent health to prevent cervical cancer and related morbidity. The annual heath care cost for the treatment of cervical cancer and genital warts is estimated to be more than three billion dollars a year. The new HPV vaccine has incredible potential to improve reproductive health promotion, reduce health care costs, and close health care disparity gaps. However, issues both for and against the new HPV vaccine, including mandating vaccination, high cost of the vaccine, the short duration of protection offered, and the perceived promotion of sexual activity, cause confusion. Pediatric nurses, including those in advanced practice, benefit by understanding the pros and cons of these issues in advocating for their patients.
Thomas
Tami L
TL
Medical College of Georgia, Department of Biobehavioral Nursing, School of Nursing, Augusta, GA, USA.
D000293:Adolescent; D002648:Child; D003218:Condylomata Acuminata / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D017281:Cost of Illness; D034462:Dissent and Disputes; D016527:Drug Costs; D005260:Female; D006293:Health Promotion; D006801:Humans; D007115:Immunization Schedule; D037141:Mandatory Programs; D032541:Mass Vaccination; D030361:Papillomavirus Infections / Q000150:complications / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000009:adverse effects / Q000191:economics / Q000276:immunology; D010371:Pediatric Nursing; D012449:Safety; D012736:Sex Education; D014481:United States / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D014611:Vaccination / Q000191:economics / Q000451:nursing
D053918:Papillomavirus Vaccines